[Comment] The decade that changed hepatocellular carcinoma: shaping a new treatment paradigm | ClinicLens

A decade ago, advances in the systemic treatment of advanced hepatocellular carcinoma had been stalled for some time. Sorafenib, the first multikinase inhibitor used to treat advanced hepatocellular carcinoma, had been approved in 2007 based on a modest survival benefit compared

Medical Literature · Updated 2026-08-10

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.